This review focuses on the potential of yeast killer toxin (KT)-like antibodies (KTAbs), that mimic a wide-spectrum KT through interaction with specific cell wall receptors (KTR) and their molecular derivatives (killer mimotopes), as putative new tools for transdisease anti-infective therapy. KTAbs are produced during the course of experimental and natural infections caused by KTR-bearing micro-organisms. They have been produced by idiotypic vaccination with a KT-neutralizing mAb, also in their monoclonal and recombinant formats. KTAbs and KTAbs-derived mimotopes may exert a strong therapeutic activity against mucosal and systemic infections caused by eukaryotic and prokaryotic pathogenic agents, thus representing new potential wide-spectrum antibiotics. © 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
Magliani, W., Conti, S., Salati, A., Vaccari, S., Ravanetti, L., Maffei, D. L., & Polonelli, L. (2004, October). Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Research. https://doi.org/10.1016/j.femsyr.2004.06.010